about
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsA new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.Locally advanced paranasal sinus carcinoma: A study of 30 patientsSquamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.Two Case Reports of Biliary Tract Injuries during Laparoscopic Cholecystectomy.Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.Latest developments in targeted therapy for hepatocellular carcinoma.Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Nanotech revolution for the anti-cancer drug delivery through blood-brain barrier.Chemotherapy in the management of brain metastases: the emerging role of fotemustine for patients with melanoma and NSCLC.The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.Erlotinib: early clinical development in brain cancer.Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.Adherence and safety of regorafenib for patients with metastatic colorectal cancer: observational real-life study.Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity.A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1).Epigenetic control of gene expression: Potential implications for cancer treatment.Humerus Metastasis From Cholangiocarcinoma: A Case Report.Impact of anemia management with EPO on psychologic distress in cancer patients: results of a multicenter patient survey.Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.Pembrolizumab: the value of PDL1 biomarker in head and neck cancer.Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.The best partner for radiotherapy after induction chemotherapy in a larynx preservation strategy.Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients.ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment.Editorial: target therapy in brain tumours and metastases.MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinomaPharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?Acceptance and adherence of oral endocrine therapy in women with metastatic breast cancer: exacampania group studyMaintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer
P50
Q26741201-DEC7ECC5-5E26-4B58-8FA7-1CB1E1CB33C5Q28740575-8F80DFE6-2FC0-4753-BFC5-725F6BBFA394Q33391296-4B711696-BCB9-4EB7-8CF8-BF4829A6CCCCQ33598253-03980D89-E349-4D9E-8477-5EF781EE717FQ33778427-0FDEF76A-C3A4-4564-A206-ED5E90263C2FQ34109952-9D16B0B5-28BE-4A83-B7A7-151FBF2EC6D5Q35064862-CA200914-E3CA-4BC8-B746-C0D1183BA2EFQ35200960-5CF74C69-0D92-4437-8168-A4009E532B5CQ36393088-6FFC5B72-B83F-4470-92E2-85B23864B713Q37799829-10376A8F-A51B-4E46-8AF4-84471B2DB672Q37870216-C25CE9B9-0BE7-41D5-8420-2A5DCE7771A4Q37977973-A5675027-9B1F-4256-A206-E0425ACB1310Q38096437-AE965D78-D422-4902-B971-BE66C7C6F7CBQ38148218-77DC220A-C8C7-434D-B28E-EB43D72C3B27Q38212394-CC6F2513-187C-4177-8FA2-8C981AEE051AQ38638654-2023441F-7328-4320-BF4B-D317D30ADFE5Q38805622-DA5E1FEF-42FC-4680-B253-39E7BEE01FA7Q38807206-195C3AA2-97C9-4CA7-BD95-442249935245Q38891976-7BA50D1D-6802-40AC-B110-DE74DDF2D9E6Q38995416-87ACC990-0512-417F-9CAD-ED8916B12514Q39161429-E9429E75-7AC3-4A10-B0DE-BE09E601DCABQ39245719-B8270C10-09CB-4332-B24A-5C375F19857AQ39297030-34864802-B80F-42FC-8778-B1F7A811E938Q39756468-C8B68D65-31A8-48E1-9CFD-6CB96207B662Q40189478-184556F5-5EBA-4533-A082-B05A55866BA1Q40654130-72B72211-3823-4A00-8F7C-E999DE017064Q42939138-33ED8469-5908-416B-91C4-C62F3B46FA31Q43735132-B26C14D6-13FF-4BFA-8703-837FF1381206Q43831814-048D8AF4-0F03-4D0F-B630-7EBA46F223FEQ44317546-3A25D17E-65EA-4D3F-B7EA-1078C0D73773Q48077245-5B98DE5A-8631-4AFA-AC00-5DD4F426CB00Q48155003-D98C58B4-E19F-4CAF-ACBB-98B5AD4539D3Q48696604-0BF1DCBB-40A2-4308-8ABF-30786BC655CEQ52958254-2818D1F0-D8B4-4AB9-B9B5-CE45CB81573EQ53746696-6427D029-6C64-4969-AECE-C3DA8DFA93CAQ83461338-CFFA40BA-1650-4D69-8247-E2BFEA8973B2Q85262602-0FF0C1BC-0C9C-40C3-A421-B42E171B9500Q85296682-7838D89F-ADA8-4121-92A3-7605EF32B1A8Q86959273-22EF185E-90EA-49EC-AA6E-4AFCAA900BB4Q91299532-8989252C-6406-41C6-B76C-8E660F633148
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Raffaele Addeo
@ast
Raffaele Addeo
@en
Raffaele Addeo
@es
Raffaele Addeo
@nl
type
label
Raffaele Addeo
@ast
Raffaele Addeo
@en
Raffaele Addeo
@es
Raffaele Addeo
@nl
prefLabel
Raffaele Addeo
@ast
Raffaele Addeo
@en
Raffaele Addeo
@es
Raffaele Addeo
@nl
P106
P21
P31
P496
0000-0001-9197-8060